Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-2243a in Advanced Solid Tumors
NCT06644755Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 1, open-label trial of DS-2243 in synovial sarcoma (SS), myxoid round cell liposarcoma (MRCLPS), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities up to 18 months, Treatment-Emergent Adverse Events up to 3 years and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
DS-2243
03
Conditions
synovial sarcoma (SS)myxoid round cell liposarcoma (MRCLPS)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06644755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644755.